Clinical trials: Relapsed/Refractory Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.
- Trial name
- NCT03494179
- Testing
- ICP-022
- Where
- 31 sites in China
- Volunteers
- 106 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Follicular Lymphoma
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
This study aims to evaluate how well the effectiveness of the medicine Tazemetostat works in adults with relapsed/refractory follicular lymphoma, a slow-growing type of blood cancer that affects a kind of white blood cell called…
- Trial name
- NCT07282548
- Sponsor
- Ipsen
Follicular Lymphoma
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel…
- Trial name
- NCT06794268
- Testing
- Lisocabtagene maraleucel
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Lymphoma, Non-Hodgkin
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic…
- Trial name
- NCT04434196
- Testing
- CC-99282, Obinutuzumab
- Where
- 15 sites in United States, Austria and 2 more
- Volunteers
- 16 people
- Sponsor
- Celgene
CLL / SLL, CLL (Chronic Lymphocytic Leukemia)
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax (ZE50-0134) in adults with relapsed or refractory chronic…
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
- Trial name
- NCT06708897
- Testing
- Lonitoclax (ZE50-0134)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Leukemia, Lymphoma
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive…
- Trial name
- NCT00884286
- Testing
- Aplidin®
- Where
- 12 sites in France, Italy and 4 more
- Volunteers
- 67 people
- Sponsor
- PharmaMar
Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-directed CAR-T cell therapy manufactured t…The goal of this Phase II single-arm, open-label clinical trial is to…
- Conditions
- Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT07713459
- Testing
- CART Infusion
- Volunteers
- 105 people
- Sponsor
- Kure Cells, INC
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT07082686
- Testing
- ICP-248
- Where
- 29 sites in China
- Volunteers
- 75 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Lymphoma, Lymphoma, Non-Hodgkin
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
This research study will test OT-82, which is an investigational ("research" or "experimental" ) drug. The study has two stages (Stage 1 and Stage 2).
- Conditions
- Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell
- Trial name
- NCT03921879
- Testing
- OT-82 Dose Escalation, OT-82 Dose Expansion
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Oncotartis, Inc.
B-cell Lymphoma
A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas
CAR-T cell therapy is a type of treatment for people with certain lymphomas. T-cells are white blood cells that help to fight infections. CAR-T cell therapy improves the body's T-cells to help them better fight cancer cells.
- Trial name
- NCT06248086
- Testing
- ASP2802, MA-20
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
- Trial name
- NCT01492088
- Testing
- Brentuximab vedotin
- Where
- 18 sites in United States, France and 6 more
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Peripheral T-cell Lymphoma
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
- Trial name
- NCT07234162
- Testing
- Golidocitinib, Chidamide, Gemcitabine
- Where
- 51 sites in China, Taiwan and 1 more
- Volunteers
- 218 people
- Sponsor
- Dizal Pharmaceuticals
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb